Literature DB >> 29383433

Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements.

Felice D'Arco1,2, Patricia O'Hare3, Fatima Dashti4, Alvaro Lassaletta5, Thalia Loka3, Uri Tabori5, Giacomo Talenti6, Stefanie Thust7, Giancarlo Messalli8, Patrick Hales9, Eric Bouffet5, Suzanne Laughlin4.   

Abstract

PURPOSE: We report a retrospective comparison between bi-dimensional RANO criteria and manual volumetric segmentation (MVS) in pediatric low-grade gliomas.
METHODS: MRI FLAIR or T1 post contrast images were used for assessment of tumor response. Seventy patients were included in this single center study, for each patient two scans were assessed ("time 0" and "end of therapy") and response to therapy was evaluated for both methods. Inter-reader variability and average time for volumetric assessment were also calculated.
RESULTS: Fourteen (20%) of the 70 patients had discordant results in terms of response assessment between the bi-dimensional measurements and MVS. All volumetric response assessments were in keeping with the subjective analysis of tumor (radiology report). Of the 14 patients, 6 had stable disease (SD) on MVS and progressive disease (PD) on 2D assessment, 5 patients had SD on MVS and partial response (PR) on 2D assessment, 2 patients had PD on MVS and SD on 2D assessment, and 1 patient had PR on MVS and SD on 2D analysis. The number of discordant results rises to 21(30%) if minor response is integrated in the response assessment. MVS was relatively fast and showed high inter-reader concordance.
CONCLUSION: Our analysis shows that therapeutic response classification may change in a significant number of children by performing a volumetric tumor assessment. Furthermore, MVS is not particularly time consuming and has very good inter-reader concordance.

Entities:  

Keywords:  MRI; Pediatric low-grade gliomas; RANO; Tumor response; Volumetric

Mesh:

Substances:

Year:  2018        PMID: 29383433     DOI: 10.1007/s00234-018-1979-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  31 in total

Review 1.  Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.

Authors:  Stephen W Gilheeney; Mark W Kieran
Journal:  Future Oncol       Date:  2012-05       Impact factor: 3.404

2.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Authors:  Matthew Mistry; Nataliya Zhukova; Daniele Merico; Patricia Rakopoulos; Rahul Krishnatry; Mary Shago; James Stavropoulos; Noa Alon; Jason D Pole; Peter N Ray; Vilma Navickiene; Joshua Mangerel; Marc Remke; Pawel Buczkowicz; Vijay Ramaswamy; Ana Guerreiro Stucklin; Martin Li; Edwin J Young; Cindy Zhang; Pedro Castelo-Branco; Doua Bakry; Suzanne Laughlin; Adam Shlien; Jennifer Chan; Keith L Ligon; James T Rutka; Peter B Dirks; Michael D Taylor; Mark Greenberg; David Malkin; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Uri Tabori
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Impact of MRI head placement on glioma response assessment.

Authors:  Martin Reuter; Elizabeth R Gerstner; Otto Rapalino; Tracy T Batchelor; Bruce Rosen; Bruce Fischl
Journal:  J Neurooncol       Date:  2014-02-25       Impact factor: 4.130

4.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution.

Authors:  C Colin; L Padovani; C Chappé; S Mercurio; D Scavarda; A Loundou; F Frassineti; N André; C Bouvier; A Korshunov; G Lena; D Figarella-Branger
Journal:  Neuropathol Appl Neurobiol       Date:  2013-10       Impact factor: 8.090

6.  Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group.

Authors:  Katherine E Warren; Tina Y Poussaint; Gilbert Vezina; Darren Hargrave; Roger J Packer; Stewart Goldman; Patrick Y Wen; Ian F Pollack; David Zurakowski; Larry E Kun; Michael D Prados; Stefan Rutkowski; Mark W Kieran
Journal:  Pediatr Blood Cancer       Date:  2013-04-26       Impact factor: 3.167

7.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 8.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

9.  Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

Authors:  Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

10.  Semi-automated segmentation of pre-operative low grade gliomas in magnetic resonance imaging.

Authors:  Zeynettin Akkus; Jiri Sedlar; Lucie Coufalova; Panagiotis Korfiatis; Timothy L Kline; Joshua D Warner; Jay Agrawal; Bradley J Erickson
Journal:  Cancer Imaging       Date:  2015-08-14       Impact factor: 3.909

View more
  5 in total

1.  Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies.

Authors:  L A Gilligan; M D DeWire-Schottmiller; M Fouladi; P DeBlank; J L Leach
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

Review 2.  Current concepts in radiologic assessment of pediatric brain tumors during treatment, part 1.

Authors:  Felice D'Arco; Sinead Culleton; Laurens J L De Cocker; Kshitij Mankad; Jorge Davila; Benita Tamrazi
Journal:  Pediatr Radiol       Date:  2018-07-06

3.  Development and Practical Implementation of a Deep Learning-Based Pipeline for Automated Pre- and Postoperative Glioma Segmentation.

Authors:  E Lotan; B Zhang; S Dogra; W D Wang; D Carbone; G Fatterpekar; E K Oermann; Y W Lui
Journal:  AJNR Am J Neuroradiol       Date:  2021-12-02       Impact factor: 3.825

4.  Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.

Authors:  Margot A Lazow; Martijn T Nievelstein; Adam Lane; Pratiti Bandopadhayhay; Mariko DeWire-Schottmiller; Maryam Fouladi; John W Glod; Robert J Greiner; Lindsey M Hoffman; Trent R Hummel; Lindsay Kilburn; Sarah Leary; Jane E Minturn; Roger Packer; David S Ziegler; Brooklyn Chaney; Katie Black; Peter de Blank; James L Leach
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

5.  Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas.

Authors:  Krskova Lenka; Zapotocky Michal; Misove Adela; Vicha Ales; Broz Petr; Vanova Katerina; Sumerauer David; Stolova Lucie; Sramkova Lucie; Koblizek Miroslav; Zamecnik Josef; Kyncl Martin; Holubova Zuzana; Liby Petr; Taborsky Jakub; Benes Vladimir; Pernikova Ivana; Jones T W David; Sill Martin; Stancokova Terezia
Journal:  Acta Neuropathol Commun       Date:  2022-09-26       Impact factor: 7.578

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.